sb 203580 has been researched along with artesunic acid in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (artesunic acid) | Trials (artesunic acid) | Recent Studies (post-2010) (artesunic acid) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 2,089 | 443 | 1,182 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beccafico, S; Donato, R; Marchetti, MC; Morozzi, G; Riccardi, C; Sidoni, A; Sorci, G | 1 |
1 other study(ies) available for sb 203580 and artesunic acid
| Article | Year |
|---|---|
Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Apoptosis; Artemisinins; Artesunate; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA Damage; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Integrin beta1; Mice; MicroRNAs; Neoplasm Invasiveness; Neoplasm Transplantation; Neural Cell Adhesion Molecules; p38 Mitogen-Activated Protein Kinases; PAX7 Transcription Factor; Pyridines; Reactive Oxygen Species; Rhabdomyosarcoma, Embryonal; Transplantation, Heterologous | 2015 |